Etonogestrel implant in women with diabetes mellitus

European Journal of Contraception and Reproductive Health Care

Volumn 13, Issue 4, 2008, Pages 387-395

  Vicente, Lisa ^a,c   Mendonca, Denisa ^b   Dingle, Marina ^a   Duarte, Rui ^a   Manuel Boavida, J ^a  

^a Portuguese Diabetes Association   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c NONE   (Portugal)

Author keywords

Contraception; Diabetes mellitus; Etonogestrel; Implanon; Implant; Progestogen only implant

Indexed keywords

CHOLESTEROL; ETONOGESTREL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; 3 KETO DESOGESTREL; 3-KETO-DESOGESTREL; ANTIDIABETIC AGENT; CONTRACEPTIVE AGENT; DESOGESTREL; GLYCOSYLATED HEMOGLOBIN;

ACNE; ADOLESCENT; ADULT; ALBUMINURIA; AMENORRHEA; ARTICLE; BLEEDING; BODY MASS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; HORMONAL CONTRACEPTION; HUMAN; IMPLANT; LIPID METABOLISM; MASTALGIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL; DRUG EFFECT; DRUG IMPLANT; METABOLISM;

ADULT; BODY MASS INDEX; CARBOHYDRATE METABOLISM; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG IMPLANTS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; PROSPECTIVE STUDIES;

EID: 64749112288     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180802382604     Document Type: Article

References (30)

1. World Health Organization. The medical eligibility criteria for contraceptive use, 3rd ed., 2004. Accessed at http:// www.who.int/topics/ reproductive-health/en/
2. ACOG Practice Bulletin N.73 Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006;107:1453-72.
3. UK Medical eligibility criteria for contraceptive use. 2005/2006. Accessed at www.fffprhc.org.uk
4. Schwarz EB, Maselli J, Gonzales R. Contraceptive counseling of diabetic women of reproductive age. Obstet Gynecol 2006;107:1070-4.
5. Napoli A, Colatrella A, Botta R, et al. Contraception in diabetic women: An Italian study. Diabetes Res Clin Pract 2005;67:267-72.
6. Kimmerle R, Schmitt G, Berger M. Empfängnisverhu ̈tung bei Typ-I-Diabetikerinnen: Eine Erhebung bei 808 Frauen in fertilen Alter. (Contraception in patients with type 1 diabetes: A survey of 808 women of reproductive age). Geburtshilfe Frauenheilkd 1994;54: 691-6.
7. Visser J, Snel M, Van Vliet HAAM. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. Cochrane Database of Systematic Reviews 2006, issue 4. Art. No:CD003990. DOI:10.1002/14651858. CD003990.pub3.
8. Godsland IF, Crook D. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. AmJ Obstet Gynecol 1994;170: 1528-36.
9. Godsland IF. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375-81.
10. Godsland IF, Walten C, Felten C, et al. Insulin resistance, secretion and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992;74:64-70.
11. Petersen KR. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull 2002;49:43-60.
12. Crook D, Godsland IF, Worthing M, et al.Acomparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Am J Obstet Gynecol 1993;169:1183-9.
13. Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002;65: 47-62.
14. Edwards JE, Moore A. Implanon. A review of clinical studies. Br J Fam Plann 1999;24(Suppl. 4):3-16.
15. Biswas A, Viegas OAC, Bennink HJTC, et al. Implanon contraceptive implants: Effects on cardohydrate metabolism. Contraception 2001;63:137-41.
16. Biswas A, Viegas OAC, Roy AC. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids. A randomized comparative study. Contraception 2003;68:189-93.
17. Suherman SK, Affandi B, Korver T. The effect of Implanon on lipid metabolism in comparison with Norplant. Contraception 1999;60:281-7.
18. Mascarenhas L, van Beek A, Bennink HC, Newton J. Twenty-four months comparison of apolipoproteins AI, AII and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom. Contraception 1998;58:215-9.
19. Hickey A, d'Arcangues C. Vaginal bleeding disturbances and implantable contraceptives. Contraception 2002;65: 75-84.
20. Kiriwat O, Patanayindee A, Koetsawang S, et al. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998;3:85-91.
21. Mansour D, Korver T, Petrova-Marintcheva M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008; 13(Suppl. 1):13-18.
22. Sergent F, Clamageran C, Bastard AM, et al. Acceptabilite ' de l'implant contraceptif a l'e'tonogestrel (Acceptability of the contraceptive etonogestrel implant.) J Gynecol Obstet Biol Reprod 2004;33:407-15.
23. Belsey EM, Farley TMM. The analysis of menstrual bleeding patterns. A review. Contraception 1988;38:129- 56.
24. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetic Association. Diabetes Care 2007;30:162-72.
25. Hohmann H, Creinin M. The contraceptive implant. Clin Obstet Gynecol 2007;50:907-17.
26. Brache V, Faundes A, Alvarez F, Cochon L. Nonmenstrual adverse events during use of implantable contraceptives for women: Data from clinical trials. Contraception 2002;65:63-74.
27. Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception 1998;58: 109S-115S.
28. Funk S, Miller MM, Mishell DR, et al. A multicentre efficacy and safety study of the contraceptive implant containing etonogestrel. Contraception 2005;71:319-26.
29. Glasier AF, Smith KB, Spudy ZM, et al. Amenorrhea associated with contraception -An international study on acceptability. Contraception 2003;67:1-8.
30. Meirik O, Fraser IS, D'Arcangues C. Implantable contraceptives for women. Hum Reprod Update 2003;9: 49-59.